Purdue Pharma's new drug Targiniq ER is an extended release
tablet that blends oxycodone the active ingredient in OxyContin with the
FDA regulators accredited the drug for daily,
round-the-clock pain that does not react to other medications.
If abusers pulverize the tablets for snorting or injecting
naloxone blocks the rhapsodic effects of oxycodone, making the drug more hard
Naloxone is now utilized to reverse the overdose effects of
opioids, highly addictive painkilling drugs including morphine, methadone,
codeine and others.
The FDA notes that Targiniq can still be abused by simply
swallowing the tablets, the most common way of painkiller abuse.
The Administration has been under pressure to combat the
national epidemic of prescription opioid abuse.
Deaths related to addictive medications like OxyContin and
Vicodin have increased fourfold since 1990 to an estimated 16,500 in 2010, the
most recent year for which the Centers for Disease Control and Prevention
Doctors prescribe opioids for a wide range of diseases, from
post-surgical pain to arthritis and migraines.
Stamford, Connecticut-based Purdue has often been cited by
health experts as a key contributor to the over prescribing of opioids.
In 2007, Purdue Pharma and three of its executives paid $634
million and pleaded guilty to charges of providing wrong ideas to the public
about the safety and addictiveness of OxyContin.
Since then the pharmaceutical company
introduced a harder-to-abuse version of OxyContin that is designed to resist
crushing, chewing and dissolving.
Dr. Sharon Hertz of the FDA commented that the
Administration is committed to combating the misuse of all opioids, and the
development of opioids that are harder to abuse is needed in order to help address
the public health crisis of prescription drug abuse.
The FDA is requiring Purdue to carry out long-term follow-up
researches tracking rates of abuse, addiction, overdose and death with
Those requirements are benchmark for all extended release
opioid drugs approved in the State.